ArticleCurrent medicinal chemistry2026
Machine Learning, Virtual Screening and Bioactivity Evaluation to Identify AJ-292/12941271 as an Anti-proliferative Agent and Target mTOR Protein.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe objective of this study is to obtain inhibitors against mTOR targets with virtual screening, dynamic simulation and bioactivity assessment. This pursuit aims to obtain a rapid and accurate method for the discovery of new mTOR inhibitors.
methodsFirstly, the researchers obtained nearly 9000 compounds by using ROC-guided machine learning from a library of over 200000 compounds. Secondly, virtual screening was used to evaluate the affinity of 45 compounds. Further analysis was performed to identify 6 hit compounds. Simultaneously, MTT antitumor activity evaluation and kinase inhibition assays are conducted for the active compounds to discern the most promising candidates. Furthermore, AO staining and JC-1 assays are performed for the selected compounds. Simultaneously, MTT antitumor activity evaluation and kinase inhibition assays are conducted for the active compounds to discern the most promising candidates. Furthermore, AO staining, JC-1 and hemolytic toxicity evaluation assays are performed for the selected compounds.
resultsThe kinase assay demonstrates that these 6 compounds display greater sensitivity to mTOR than to PI3K. Among them, compounds AJ-292/12941271 and AG-205/12550019 show better activity against mTOR target than PI3K, with an IC50 of 2.55 and 4.48 μM, respectively. Additionally, the anti-proliferative activity of the six hit compounds was also considered. Compound AJ-292/12941271 shows the best anticancer activity against A549 cell lines with an IC50 value of 4.3 μM. Further analysis reveals that compound AJ-292/12941271 induces apoptosis in the A549 cell line in a concentration- dependent or time-dependent manner. Hemolytic toxicity evaluation suggests that the compound AJ-292/12941271 is safe for further in vivo study.
conclusionThis research proposes that the fused method of ROC-based machine learning, virtual screening, and bioactivity evaluation could be used to discover novel mTOR inhibitors quickly and precisely.
Indexed as
Identifiers
40692147What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.